These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3987218)

  • 1. Predicting plasma procainamide concentrations resulting from a sustained-release preparation.
    DiPersio DM; Chow MS
    Clin Pharm; 1985; 4(2):186-91. PubMed ID: 3987218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride.
    Kasmer RJ; Nara AR; Green JA; Chawla AK; Fleming GM
    Drug Intell Clin Pharm; 1987 Feb; 21(2):183-6. PubMed ID: 3829910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of steady-state trough serum procainamide concentrations after administration of a sustained-release procainamide preparation.
    Voelker MS; Nester TJ; Chow MS; O'Reilly D; Kluger J
    Ther Drug Monit; 1986; 8(2):184-8. PubMed ID: 3726932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release procainamide: use of serum concentrations to determine dosage.
    Reed WE; Cooper MW
    South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative bioavailability of two oral sustained-release procainamide products.
    Baker BA; Reynolds JR; Gleckel L; A'Zary E; Bodenheimer MM
    Clin Pharm; 1988 Feb; 7(2):135-8. PubMed ID: 3349748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method of determining the in vivo drug release rate constant of sustained-release preparation.
    Sun H; Chow MS
    Drug Metab Dispos; 1995 Apr; 23(4):449-54. PubMed ID: 7600910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
    Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
    J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 12. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytopenia following sustained-release procainamide.
    Meisner DJ; Carlson RJ; Gottlieb AJ
    Arch Intern Med; 1985 Apr; 145(4):700-2. PubMed ID: 2580499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an open-loop, computer-based infusion system designed to achieve a series of constant, targeted plasma procainamide concentrations in patients undergoing electrophysiologic testing.
    Coyle JD; Carnes CA; Schaal SF
    Pharmacotherapy; 1997; 17(3):445-56. PubMed ID: 9165549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo-in vitro correlations with sustained-release theophylline preparations.
    Ritschel WA; Koch HP; Alcorn GJ
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):609-18. PubMed ID: 6513678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
    Ihlen H; Skomedal T; Stafsnes H; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):257-62. PubMed ID: 805020
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.